PHARNEXT news, videos and press releases
For more news please use our advanced search feature.
PHARNEXT - More news...
PHARNEXT - More news...
- Pharnext takes full stock of its operating, strategic and financial situation
- Pharnext progresses in analyzing data from pivotal Phase III study of PXT3003 in Charcot-Marie-Tooth disease type 1A
- Pharnext commits to a drastic cost-cutting plan and receives support from its financial partners to further enhance the value of its drug candidate for Charcot-Marie-Tooth disease type 1A
- Pharnext commits to a drastic cost-cutting plan to further enhance the value of its drug candidate for Charcot-Marie-Tooth disease type 1A
- Pharnext intends to prepare registration and marketing authorization dossiers for PXT3003, its drug candidate in Charcot-Marie-Tooth disease type 1A
- Pharnext reports topline results from the pivotal Phase III clinical trial (PREMIER trial) of PXT3003 in Charcot-Marie-Tooth disease type 1A
- Pharnext announces database lock for PXT3003 pivotal Phase III clinical study (PREMIER trial) in Charcot-Marie-Tooth disease type 1A, last step before topline results publication
- Pharnext unveils new calendar for negotiations valuing its drug candidate in Charcot-Marie-Tooth disease type 1A
- Pharnext announces being at D-18 before publication of topline results from pivotal Phase III clinical trial (PREMIER trial) in Charcot-Marie-Tooth disease type 1A
- Pharnext announces successful manufacturing of registration batches of PXT3003 in the United States
- Pharnext receives a new offer valuing its drug candidate for Charcot-Marie-Tooth disease type 1A at more than EUR500m and the support of its financial partners
- Pharnext received two offers valuing its drug candidate for Charcot-Marie-Tooth disease type 1A at more than EUR 250m, and raises EUR 2.5m
- Pharnext updates on the development program in China for PXT3003 in Charcot-Marie-Tooth disease type 1A (CMT1A)
- Edison Investment Research maintains its valuation following the Company's latest announcements
- Pharnext enters the final stretch for the signature of a licensing agreement for its drug candidate in Charcot Marie Tooth disease type 1A, enabling it to capitalize on its assets and put an end to the OCEANE BSA financing line
- Pharnext reports the end of double-blind treatment in PREMIER trial, the pivotal Phase III clinical trial of PXT3003 in Charcot-Marie-Tooth disease type 1A
- Balance sheet liabilities reduced by almost EUR8 million following a debt waiver
- Pharnext shareholders approve the appointment of Guy-Charles Fanneau de La Horie to the Supervisory Board
- Pharnext appoints Gilbert Wagener, M.D., Ph.D. as Chief Medical Officer
- The Latest Findings From CMTMe, a 'Real-World' Digital Lifestyle Study on Charcot-Marie-Tooth Diseases ('CMTs'), to be Presented at the 2023 Peripheral Nerve Society ('PNS') Annual Meeting
- Pharnext supports and participates in the First European Charcot-Marie-Tooth disease Specialists Conference
- After 6 years of total trial time, data from the open-label PLEO-CMT-FU trial are consistent with a long-term benefit of PXT3003 in Charcot-Marie-Tooth Disease Type 1A (CMT1A)
- Pharnext reports significant progress in the search for pharmaceutical partners to value its assets and finance its development
- Edison Investment Research publishes updates research report on Pharnext
- Pharnext supports the upcoming Spring Meeting of the Neuromuscular Diseases Study Group of the Spanish Society of Neurology (SEN)
- Pharnext supports the online 2023 Conference of CMTUK, the UK's Charity dedicated to supporting people living with Charcot-Marie-Tooth disease
- Findings on the impact of fatigue on patients living with Charcot-Marie-Tooth diseases from 'Real-World' digital lifestyle study, CMT and Me, to be presented in a webinar organized with CMT UK
- Pharnext supports and participates in two congresses on Neuromuscular Disorders in Europe
- Pharnext supports and participates in two congresses dedicated to Charcot-Marie-Tooth diseases in Marseille, France
- New study published by Edison Investment Research updates valuation of Pharnext's assets
